# AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits AstraZeneca low cytokine release and is capable of bystander killing



Miguel Gaspar<sup>1</sup>, Marina Natoli<sup>1</sup>, Laure Castan<sup>1</sup>, Sharif Rahmy<sup>2</sup>, Cathryn Kelton<sup>2</sup>, Kathy Mulgrew<sup>2</sup>, Martin Korade III<sup>2</sup>, Oisin Huhn<sup>1</sup>, D Gareth Rees<sup>1</sup>, Anna Sigurdardottir<sup>1</sup>, Christopher Lloyd<sup>1</sup>, Yun He<sup>3</sup>, Yiping Rong<sup>3</sup>, Kristen Pollizzi<sup>2</sup>, Scott A Hammond<sup>2</sup>, Saso Cemerski<sup>2</sup>, Simon J. Dovedi<sup>1</sup>, Mark Cobbold<sup>2</sup>, Benjamin Ridgway<sup>2</sup>, Maria AS Broggi<sup>2</sup>, Douglas C Palmer<sup>2</sup>, Kathryn Ball<sup>1</sup>, Mary McFarlane<sup>1</sup>, Fred Arce Vargas<sup>1</sup>, Natalia Ceaicovscaia<sup>2</sup>, Gayle Pouliot<sup>4</sup>, Philip Szekeres<sup>5</sup>, Jonathan Fitzgerald<sup>4</sup> & Rakesh Kumar<sup>2</sup>

<sup>1</sup>AstraZeneca, Cambridge, UK; <sup>2</sup>AstraZeneca, Gaithersburg, MD, USA; <sup>3</sup>Discovery, Harbour BioMed, Shanghai, China; <sup>4</sup>AstraZeneca, Waltham, MA, USA; <sup>5</sup>AstraZeneca, Royston, UK.

**Abstract Number: 1169** 

## **Background**

Claudin 18.2 (CLDN18.2), an essential component of tight junctions in gastric epithelium, is highly expressed in gastric, pancreatic and esophageal adenocarcinoma [1] and is a validated therapeutic target in CLDN18.2-high gastric cancer [2,3]. Here we describe AZD5863, a CLDN18.2 and CD3-targeting T cell engager (TCE) designed with high CLDN18.2 and low CD3 affinity to reduce class-associated toxicities such as cytokine release syndrome while maintaining potent antitumor activity on CLDN18.2-positive cells and bystander killing of CLDN18.2negative cells (Figure 1).




Figure 1: Proposed mechanism of action for AZD5863.

## Results

#### AZD5863 is affinity-optimized and highly specific to CLDN18.2

In cell binding assays, AZD5863 showed specific binding to human CLDN18.2-expressing HEK293 cells and to CD3-expressing Jurkat cells, while it did not bind to HEK293 cells expressing CLDN18.1 (Figure 2).




Figure 2: AZD5863 binding to human CLDN18.2-expressing HEK293 cells, CLDN18.1-expressing HEK293 cells and CD3-expressing Jurkat cells.

Surface plasmon resonance (SPR) experiments showed that AZD5863 binds to human CLDN18.2 with a KD of 0.1 ± 0.04 nM and to the human CD3 $\delta\epsilon$  heterodimer protein with an interaction affinity (KD) of 170 ± 7 nM.

## AZD5863-driven T-cell dependent cellular cytotoxicity (TDCC) EC50s strongly correlate with levels of CLDN18.2 expression on a panel of human tumor cell lines

AZD5863-driven TDCC was demonstrated in vitro by co-culturing PBMCs from three donors with a panel (n=18) of human tumor cell lines. AZD5863-driven TDCC EC50 values were observed to significantly inversely correlate to levels of CLDN18.2 expression (measured by an antibody binding capacity [ABC] assay), indicative of potent and highly targetmediated AZD5863 activity (Figures 3-4). TDCC activity was consistently observed at > 1500 ABC/cell (Figures 3-4).




Figure 3: TDCC driven by AZD5863 using four representative human tumor cell lines with distinct CLDN18.2 receptor density (n=3 PBMC donors per treatment; E:T 4:1; 48 hours incubation).




Figure 4: EC50s (pM) of AZD5863-mediated TDCC strongly correlate with tumor CLDN18.2 receptor density (n=18 cell lines tested, each with n=3 PBMC donors); TDCC activity is consistently observed at a receptor density > 1500 ABC/cell (indicated by dotted line).

#### AZD5863 maintains low secretion of IL-6 and TNF-α

AZD5863 was shown to be more potent than a TCE with high affinity for both CLDN18.2 and CD3 in an in vitro TDCC assay using NUGC4. However, AZD5863 triggered lower secretion of IL-6 and TNFα in vitro as well as in vivo, 4 hours post IV dosing in a NCG (NOD-*Prkdc*<sup>em26Cd52</sup>II2rg<sup>em26Cd22</sup>/NjuCrl) model humanized with PBMCs (Figure 5).




Figure 5: AZD5863 is more potent than a High T cell affinity CD3xCLDN18.2 TCE (HTA-TCE) while triggering lower secretion of IL-6 and TNF $\alpha$ , in vitro and in vivo.

#### AZD5863 mediates bystander killing of CLDN18.2-negative cells

AZD5863 mediated bystander killing of PaTu8988s CLDN18.2-knockout (KO) cells only when these were co-cultured (for two days) with CLDN18.2 positive PaTu8988s (WT, sorted for high CLDN18.2 expression), a pancreatic cancer cell line, and PBMCs (Figure 6).




Figure 6: AZD5863 shows potent bystander killing of PaTu8988s CLDN18.2 KO cells when these are co-cultured with CLDN18.2+ cells (PaTu8988s CLDN18-2high sorted [HS]).

AZD5863 induces tumor growth inhibition in humanized mouse models for gastric, pancreatic and esophageal tumors as well as in a human CD3 knock-in mouse model bearing moCLDN18.2-expressing MC38

In vivo, IP administration of AZD5863 mediated potent tumor growth inhibition in immunodeficient (NOD.Cg-Prkdc<sup>scid</sup> II2rg<sup>tm1Wjl</sup>/SzJ, i.e. NSG) mice implanted with different human tumor cell lines - humanized with either CD3/CD28-activated hPBMCs or using unstimulated PBMCs in an admix model (NUGC4) - as well as in immunocompetent human CD3 knock-in mice implanted with murine CLDN18.2-expressing MC38 cells.




Figure 7: AZD5863 mediates tumor growth inhibition in humanized models and in syngeneic human CD3 knock-in mice implanted with CLDN18.2-expressing MC38 cells.

## **Conclusions**

- AZD5863, an affinity-optimized TCE targeting CLDN18.2 and CD3, demonstrated potent and specific pre-clinical antitumor activity both in vitro and in vivo, induced bystander killing of CLDN18.2-negative tumor cells and low secretion of IL-6 and TNF $\alpha$ .
- A phase 1 trial testing AZD5863 in gastric, pancreatic and esophageal adenocarcinoma, is ongoing (NCT06005493).

# References

1. Sahin et al. Clin Cancer Res (2008) 2. Shitara et al. J Clin Oncol. (2023) 3. Xu et al. J Clin Oncol. (2023)